PharmacoEconomics & Outcomes News 690, p11 - 2 Nov 2013 T2DM market to double in next decade The market for type 2 diabetes drugs will nearly double over the next decade, increasing from $US27 billion in 2012 to $47 billion in 2022 in the US, France, Germany, Italy, Spain, the UK and Japan, according to a report from Decision Resources. 1 Both an increase in the drug-treated patient population, and increased use of currently available drugs and soon-to- launch emerging branded agents during this period are the main factors for this expected growth. Of note, sales for the market-leading DPP-IV inhibitors [CD26 antigen-inhibitors] class will peak at almost $14 billion before the first generic entrant of the class (saxagliptin) in 2021. While generic entry of sitagliptin in 2022 will lead to significant sales erosion of the class, this should not threaten their market-leading position. Endocrinologists want data on biosimilar insulins Meanwhile, a second report from Decision Resources, finds that surveyed endocrinologists in the US and Europe want extensive efficacy data from multiple Phase III trials, before they "feel comfortable" prescribing biosimilar insulins. 2 The European Medicines Agency (EMA) says there is no anticipated need for specific efficacy trials for approval, but endocrinologists appear to want more data before they are ready to adopt biosimilars. "These findings suggest that a high level of investment in clinical development will be required to maximize uptake of biosimilar insulins", says Biosimilars Research Director, Kate Keeping. 1. Decision Resources. The Type 2 Diabetes Market Will Nearly Double, Increasing from $27 Billion in 2012 to $47 Billion in 2022. Media Release : 16 Oct 2013. Available from: URL: http://www.decisionresources.com. 2. BioTrends Research Group. Endocrinologists Would Prefer Extensive Efficacy Data Before Prescribing Biosimilar Insulins. Media Release : 16 Oct 2013. Available from: URL: http://www.bio-trends.com. 801085748 1 PharmacoEconomics & Outcomes News 2 Nov 2013 No. 690 1173-5503/13/0690-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved

T2DM market to double in next decade

Download PDF Report

Upload
yan-hua
View
212
Download
0

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 690, p11 - 2 Nov 2013

T2DM market to double innext decade

The market for type 2 diabetes drugs will nearlydouble over the next decade, increasing from$US27 billion in 2012 to $47 billion in 2022 in the US,France, Germany, Italy, Spain, the UK and Japan,according to a report from Decision Resources.1 Both anincrease in the drug-treated patient population, andincreased use of currently available drugs and soon-to-launch emerging branded agents during this period arethe main factors for this expected growth.

Of note, sales for the market-leading DPP-IVinhibitors [CD26 antigen-inhibitors] class will peak atalmost $14 billion before the first generic entrant of theclass (saxagliptin) in 2021. While generic entry ofsitagliptin in 2022 will lead to significant sales erosion ofthe class, this should not threaten their market-leadingposition.

Endocrinologists want data on biosimilarinsulins

Meanwhile, a second report from DecisionResources, finds that surveyed endocrinologists in theUS and Europe want extensive efficacy data frommultiple Phase III trials, before they "feel comfortable"prescribing biosimilar insulins.2

The European Medicines Agency (EMA) says there isno anticipated need for specific efficacy trials forapproval, but endocrinologists appear to want moredata before they are ready to adopt biosimilars. "Thesefindings suggest that a high level of investment in clinicaldevelopment will be required to maximize uptake ofbiosimilar insulins", says Biosimilars Research Director,Kate Keeping.1. Decision Resources. The Type 2 Diabetes Market Will Nearly Double,

Increasing from $27 Billion in 2012 to $47 Billion in 2022. Media Release : 16Oct 2013. Available from: URL: http://www.decisionresources.com.

2. BioTrends Research Group. Endocrinologists Would Prefer Extensive EfficacyData Before Prescribing Biosimilar Insulins. Media Release : 16 Oct 2013.Available from: URL: http://www.bio-trends.com.

801085748